Samhällsekonomiska kostnader kopplade till typ 1-diabetes i Sverige år 2023

Hedda Carlsson, Katarina Gralén, Adam Fridhammar and Sofie Persson
Additional contact information
Hedda Carlsson: IHE - The Swedish Institute for Health Economics
Katarina Gralén: IHE - The Swedish Institute for Health Economics
Adam Fridhammar: IHE - The Swedish Institute for Health Economics
Sofie Persson: IHE - The Swedish Institute for Health Economics

No 2025:15, IHE Report / IHE Rapport from IHE - The Swedish Institute for Health Economics

Abstract: What is this report about?

Type 1 diabetes is a lifelong chronic disease that typically begins in childhood and requires extensive self-care throughout life. The disease places a significant burden on those affected, their families, and society at large. Despite this, there are relatively few studies that estimate the specific costs associated with type 1 diabetes, particularly in a Swedish context. The aim of this study was therefore to calculate the societal costs related to type 1 diabetes in Sweden for the year 2023.

How were the analyses conducted?

The analysis was carried out in two steps. In the first step, the costs associated with type 1 diabetes as a specific diagnosis were estimated. These included costs for healthcare, pharmaceuticals, medical devices, support resources in schools and preschools, as well as productivity losses, both for individuals with the disease and for parents of children with type 1 diabetes. In the second step, costs related to complications linked to type 1 diabetes, such as cardiovascular disease, kidney problems, and other long-term consequences, were estimated. To determine what proportion of these costs could be attributed to type 1 diabetes, so-called attribution factors were used. These were applied to existing cost data from other studies or to specially developed cost estimates.

What do the results show?

The results show that type 1 diabetes entails substantial societal costs in Sweden. For the year 2023, the total costs were estimated at SEK 12.9 billion. Of this, SEK 8.6 billion were direct costs related to the disease itself, while SEK 4.3 billion were related to complications. The largest cost components were medical devices, productivity losses due to illness, and support resources in schools and preschools. Total productivity losses, including those affecting parents, amounted to SEK 2.8 billion. Among the complications, cardiovascular disease accounted for the largest share of costs. Overall, the study demonstrates that type 1 diabetes impacts many areas of society and that the associated costs are both extensive and complex. The results highlight the need for effective treatment strategies, preventive measures against complications, and supportive societal interventions to reduce the economic burden in the future.

Keywords: Diabetes; Typ 1-diabetes; Diabeteskomplikationer; Samhällsekonomiska kostnader (search for similar items in EconPapers)
Pages: 34 pages
Date: 2025
Note: The report is written in Swedish with a summary in English
References: Add references at CitEc
Citations:

Downloads: (external link)
https://ihe.se/app/uploads/2025/10/IHE-RAPPORT-2025_15_.pdf Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hhs:ihewps:2025_015

Access Statistics for this paper

More papers in IHE Report / IHE Rapport from IHE - The Swedish Institute for Health Economics
Bibliographic data for series maintained by Annette Persson Dietmann ().